||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Sareum Share Discussion Threads
Showing 27401 to 27424 of 27425 messages
|Target price 4.5p......just for starters.|
|Why would there be news next week?|
|news next week?|
|Coming back Bobby. Don't fret!|
|Bloody hell, another drop!|
|lol bobby. Luckily, they've got roughly 45 years until they can touch it. One way or the other, SAR will have done its thing by then!! ;)|
|btfd: don't look good for their Uni fees mate!|
|good luck to you btfd. i'm sure it'll come good. A|
|Bought another £300 worth for both my kids junior Sipps, the two consecutive 33429 trades. They've got a grands worth each now, and a few large caps in there. Hopefully by the time they've finished school SAR is flying for them (or bought out!)|
|Thanks ackers and timbo003 for that and a useful synopsis of the Sierra Conference presentation last week|
|:) yeah cheap skate here|
|latest broker note
|Inserting upper case TT doesn't make it work as an active link unless you cough up however much it is nowadays to become a blue ADVFN subscriber, but it does allow a reader to copy and paste directly without replacing the xx with tt, so still worth doing.
|lol didn't work either :)|
|4.5p sounds good to me.. and heading onwards to 8p in 2018 if we aren't bought out.. thanks akkers.. here's the link with cap TshTTps://indigo.bluematrix.com/indigo/Viewer.action?info=kK07jdZm7EGz%2FWD2gYRctTo3RpFQsQDr|
|>>>ackers, thanks for the link to the hybridian report
I think the trick with the links is to go back and edit the post where ADVFN have unhelpfully altered link with using upper case T
|each time I copy the http at the start gets altered to hxx so just delete the xx and replace with tt.
|Slight correction to my earlier post. Pfizer do have a tyk2 inhibitor in the clinic. But not for RA and in Lupus it has been dropped after phase1. So it would appear while they have an interest in the area (still in trials for ibs and psoriasis) there may be issues on the molecule stopping it progressing in RA and Lupus which are the biggest market. So still think they may buy us if our molecule is demonstrably better than tbeirs|
|Listened to Sierra’s presentation at last Wednesday’s JP Morgan Bio Tech showcase-hxxp://investor.sierraoncology.com/events-and-webcasts?item=14.
A 28 odd minute presentation which gave an overview of how chk1 fits in to the overall scene-a good deal of which went over my head.
From minute 13 discussed 737 in detail; extolled the virtues of ICR and said Sierra would continue to work closely with them and the Royal Marsden and specifically namechecked Dr Ruth Plummer.
Said that they programme to release preliminary data by the end of this year and have data of a medical conference standard later in 2018 and also in 2018 look to see how they can expand the potential of 737.
I would be interested in the comments of those who have a better handle on the tech side than I have.|
|How did you folks get hold of the Hybridian note?|
|Hyrbidian note exceedingly bullish and factual.
2p should be the order of the day here, just on what has happened so far.|
|Thank you MrsApesLaptop, very good post|